These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26389773)

  • 1. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
    Williams DM; Stephens JW
    Expert Opin Pharmacother; 2015; 16(15):2373-9. PubMed ID: 26389773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
    Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
    Garnock-Jones KP
    Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.
    Coppenrath VA; Hydery T
    Ann Pharmacother; 2018 Jan; 52(1):78-85. PubMed ID: 28884600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
    Dey J
    Postgrad Med; 2017 May; 129(4):409-420. PubMed ID: 28322073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):583-592. PubMed ID: 28374622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
    Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
    Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.
    Anderson R; Hayes J; Stephens JW
    Expert Opin Drug Metab Toxicol; 2016; 12(4):467-73. PubMed ID: 26878666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
    Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
    Scheen AJ
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
    Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
    Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ; Del Prato S; Wei C; Reyner D; Saraiva G
    Diabetes Obes Metab; 2019 Nov; 21(11):2564-2569. PubMed ID: 31364269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.